Zacks Investment Research Upgrades Koninklijke DSM (OTCMKTS:RDSMY) to Hold

Share on StockTwits

Zacks Investment Research upgraded shares of Koninklijke DSM (OTCMKTS:RDSMY) from a strong sell rating to a hold rating in a report issued on Wednesday morning, reports.

According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “

Several other research firms also recently commented on RDSMY. JPMorgan Chase & Co. lifted their price objective on from GBX 2,300 ($30.05) to GBX 2,900 ($37.89) and gave the stock a neutral rating in a report on Friday, July 5th. ValuEngine downgraded Yext from a strong-buy rating to a buy rating in a report on Friday, May 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $30.00.

RDSMY opened at $31.57 on Wednesday. The stock has a market capitalization of $22.74 billion, a P/E ratio of 18.25, a P/E/G ratio of 2.23 and a beta of 1.41. The business has a 50-day moving average of $30.04. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.68 and a current ratio of 2.45. Koninklijke DSM has a 12 month low of $19.45 and a 12 month high of $31.75.

About Koninklijke DSM

Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and materials businesses in the Netherlands, North America, the United Kingdom, France, Germany, Switzerland, the Asia-Pacific, and internationally.. The company operates through Nutrition, Materials, and Innovation Center segments.

Featured Article: How is a buy-side analyst different from a sell-side analyst?

Get a free copy of the Zacks research report on Koninklijke DSM (RDSMY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with's FREE daily email newsletter.

Leave a Reply